Figure S3 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
<p>Supplementary Figure S3. Viability with niraparib and olaparib in additional clones – related to Figure 2. A) Immunoblotting analysis of POLB from 2 individual clones confirming POLB knockout in BRCA1 mutant MDA-MB-436 (left) and SUM149PT cells (right). Cl#1 of sgIntron and cl#3 of sgPOLB for MDA-MB-436 and cl#1 of sgIntron and cl#1 of sgPOLB for SUM149PT are same as in Fig. 2A. B) Dose response curves of control (cl#1) and POLB knockout (cl#5) derivatives of MDA-MB436 cells treated with niraparib (left) and dose response curves of control (cl#1) and POLB knockout (cl#2) derivatives of SUM149PT cells treated with niraparib (middle) and olaparib (right) for 7 days. Data are represented as mean +SD, N = 3. Statistical significance was derived from nonlinear regression curves of sgIntron vs. sgPOLB (****, P < 0.0001; *, 0.02).</p>
Authors
- Brian Doyon
- Madhavi Bandi (ORCID: https://orcid.org/0000-0002-7562-0170)
- Tianshu Feng (ORCID: https://orcid.org/0000-0002-9445-4876)
- William D. Mallender
- Robert Tjin Tham Sjin (ORCID: https://orcid.org/0000-0002-3809-8424)
- Jannik N. Andersen (ORCID: https://orcid.org/0000-0003-4528-2120)
- Erik Wilker (ORCID: https://orcid.org/0000-0003-4535-178X)
- Douglas A. Whittington (ORCID: https://orcid.org/0000-0002-5946-8543)
- Alan Huang (ORCID: https://orcid.org/0000-0001-5501-0212)
- Yi Yu (ORCID: https://orcid.org/0000-0002-2223-337X)
- Xuewen Pan (ORCID: https://orcid.org/0000-0002-0148-5631)
- Katherine Lazarides (ORCID: https://orcid.org/0000-0002-0878-0465)
- Shangtao Liu (ORCID: https://orcid.org/0000-0002-2724-9178)
- Hongxiang Zhang (ORCID: https://orcid.org/0000-0001-6794-0038)
- Ashley H. Choi (ORCID: https://orcid.org/0000-0002-2802-7163)
- Justin L. Engel (ORCID: https://orcid.org/0000-0002-2016-3494)
- Binzhang Shen (ORCID: https://orcid.org/0000-0002-6556-7791)
- Samuel R. Meier (ORCID: https://orcid.org/0000-0002-7026-2722)
- Brian J. McMillan (ORCID: https://orcid.org/0000-0002-3134-7774)
- Michele Meseonznik
Publication Details
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1158/1535-7163.30028934
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00